Terril Brothers Inc. Invests $5.34 Million in Solventum Co. (NYSE:SOLV)

Terril Brothers Inc. bought a new position in shares of Solventum Co. (NYSE:SOLV - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 80,856 shares of the company's stock, valued at approximately $5,341,000. Solventum makes up 1.6% of Terril Brothers Inc.'s holdings, making the stock its 17th biggest position.

A number of other institutional investors have also added to or reduced their stakes in the business. SVB Wealth LLC purchased a new stake in shares of Solventum during the 4th quarter valued at $229,000. Versor Investments LP bought a new position in Solventum in the fourth quarter valued at $263,000. Proficio Capital Partners LLC purchased a new stake in Solventum during the fourth quarter valued at about $1,545,000. New York Life Investment Management LLC lifted its stake in Solventum by 0.7% during the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company's stock worth $1,223,000 after purchasing an additional 136 shares during the last quarter. Finally, Apriem Advisors purchased a new position in shares of Solventum in the 4th quarter worth about $333,000.

Solventum Trading Down 1.5 %

Shares of SOLV traded down $1.20 during mid-day trading on Wednesday, hitting $77.79. 1,072,383 shares of the company's stock traded hands, compared to its average volume of 1,446,876. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $13.44 billion and a P/E ratio of 28.29. The business's 50-day moving average price is $73.02 and its 200-day moving average price is $70.33. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SOLV shares. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday. The Goldman Sachs Group increased their target price on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. Finally, Mizuho raised their price objective on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Solventum has a consensus rating of "Hold" and an average price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.